Juan Alonso - Genomma Lab Independent Director
| LABB Stock | MXN 25.78 0.27 1.06% |
Director
Mr. Juan Alonso serves as Independent Director of Genomma Lab Internacional, S.A.B. de C.V. He was serving as Chief Executive Officer of ZAO Future Technologies and Chairman of Domino Pizza Jalisco SA de CV. In March 2007, he holds a partnership agreement with Israel BSG Investments, the developer of real estate in Russia and the Commonwealth of Independent States, to develop nearly one million square meters of residential and commercial real estate in Russia. He is also the majority shareholder of ZAO SILVER Nizhny Novgorod, the national water bottler Nestle in Russia. Previously, he was President of Domino Pizza Jalisco, SA de CV, Master franchisee of Domino Pizza in central Mexico, as well as the majority shareholder of Baskin Robbins DF.
| Age | 52 |
| Phone | 52 55 5081 0000 |
| Web | https://www.genommalab.com |
Genomma Lab Management Efficiency
The company has return on total asset (ROA) of 0.0921 % which means that it generated a profit of $0.0921 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1264 %, meaning that it generated $0.1264 on every $100 dollars invested by stockholders. Genomma Lab's management efficiency ratios could be used to measure how well Genomma Lab manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Enrique Mejorada | Alfa SAB de | 62 | |
| Thomas Rodriguez | Grupo Financiero Banorte | 64 | |
| Joseph Russell | Gruma SAB de | 52 | |
| David Guzman | Alfa SAB de | 62 | |
| Everardo Almaguer | Gruma SAB de | 75 | |
| Luis Morales | Grupo Mxico SAB | N/A | |
| Luiz Rodrigues | Kimberly Clark de Mxico | N/A | |
| Jose Eguia | Grupo Financiero Banorte | 51 | |
| Juan Urevig | Kimberly Clark de Mxico | N/A | |
| Eduardo Cantu | Grupo Financiero Banorte | 76 | |
| Jesus Martinez | Gruma SAB de | 62 | |
| Marlene Torre | Grupo Mxico SAB | N/A | |
| Rafael Garcia | Grupo Mxico SAB | N/A | |
| Emilio Gamboa | Grupo Mxico SAB | 81 | |
| Emilio Gamboa | Kimberly Clark de Mxico | 81 | |
| Adrian Gonzalez | Alfa SAB de | 75 | |
| Carlos Curiel | Kimberly Clark de Mxico | N/A | |
| David Montemayor | Grupo Financiero Banorte | 69 | |
| Alberto Boesch | Gruma SAB de | 47 | |
| Esteban Fomperosa | Kimberly Clark de Mxico | 70 | |
| Carlos Velasco | Grupo Mxico SAB | N/A | |
Management Performance
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0921 |
Genomma Lab Internacional Leadership Team
Elected by the shareholders, the Genomma Lab's board of directors comprises two types of representatives: Genomma Lab inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genomma. The board's role is to monitor Genomma Lab's management team and ensure that shareholders' interests are well served. Genomma Lab's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genomma Lab's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Scott Emerson, Independent Director | ||
| Cesar Lopez, Vice President of Global Marketing | ||
| Efran Crdova, Deputy Sec | ||
| Carlos Alonso, Independent Director | ||
| Marianne Velasco, Global HR | ||
| Jorge Munoz, Independent Director | ||
| Ignacio Rodriguez, Independent Director | ||
| Alejandro Patino, Executive Vice President of Human Capital and Commercial Expansion | ||
| L Porres, Legal Officer | ||
| Rodrigo Aspra, Chairman of the Board, Independent Director | ||
| Juan Gavito, Independent Director | ||
| Antonio Galland, Executive Vice President, Chief Financial and Chief Administrative Officer | ||
| Hector Gonzalez, Independent Director | ||
| Burkhard Wittek, Director | ||
| Alejandro Patio, Media, Relations | ||
| Javier Castilla, Independent Director | ||
| Engineer Galland, Exec CFO | ||
| Sabrina Aspra, Director of International Operations, Director | ||
| Mximo Juda, Advisor | ||
| Daniel Neria, Head Relations | ||
| Juan Alonso, Independent Director | ||
| Santiago Pelaez, Vice President of Industrial and Research and Development | ||
| Jorge Valderrama, Chief Executive Officer | ||
| Juan Sparvieri, Chief Operating Officer, Vice President | ||
| Leticia Herrera, Global Director of Human Resources (Genomma Experience) |
Genomma Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Genomma Lab a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0921 | |||
| Profit Margin | 0.08 % | |||
| Operating Margin | 0.20 % | |||
| Current Valuation | 20.43 B | |||
| Shares Outstanding | 1 B | |||
| Shares Owned By Insiders | 29.00 % | |||
| Shares Owned By Institutions | 29.10 % | |||
| Price To Earning | 13.61 X | |||
| Price To Book | 1.51 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Genomma Stock Analysis
When running Genomma Lab's price analysis, check to measure Genomma Lab's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genomma Lab is operating at the current time. Most of Genomma Lab's value examination focuses on studying past and present price action to predict the probability of Genomma Lab's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genomma Lab's price. Additionally, you may evaluate how the addition of Genomma Lab to your portfolios can decrease your overall portfolio volatility.